title: How can nanoparticles contribute to antituberculosis therapy?
abstract: Therapeutic approaches using nanoparticles are being successfully used in foods and in several fields of medicine, including infectious diseases. Regarding tuberculosis (TB) treatment, nanoparticles can be a useful strategy for two distinct applications: (i) for their intrinsic antimycobacterial activity; (ii) as vehicles for known antitubercular drugs to allow reduction of dose- and drug-associated side-effects and administration via user-friendly administration routes such as pulmonary or oral ones. Promising results were obtained in vitro and in animal Mycobacterium tuberculosis models and need now to be translated into clinical drug candidates. Such a prospect can provide an opportunity regarding the current limited therapeutic options for drug-resistant TB and the scarcity of novel antituberculosis drugs in the drug discovery pipeline.
authors.affiliation: University of Lille, CNRS, INSERM, University Hospital Center of Lille, Pasteur Institute of Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, 59000 Lille, France.
authors.forename: Joana
authors.initials: J
authors.lastname: Costa-Gouveia
authors.affiliation: Departamento de Microbiología (Facultad de Medicina), and BIFI, Universidad de Zaragoza, Zaragoza, Spain; Instituto de Investigación Sanitaria Aragón (IIS-Aragón), Zaragoza, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
authors.forename: José A
authors.initials: JA
authors.lastname: Aínsa
authors.affiliation: University of Lille, CNRS, INSERM, University Hospital Center of Lille, Pasteur Institute of Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, 59000 Lille, France. Electronic address: priscille.brodin@inserm.fr.
authors.forename: Priscille
authors.initials: P
authors.lastname: Brodin
authors.affiliation: Departamento de Microbiología (Facultad de Medicina), and BIFI, Universidad de Zaragoza, Zaragoza, Spain; Instituto de Investigación Sanitaria Aragón (IIS-Aragón), Zaragoza, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: ainhoalq@unizar.es.
authors.forename: Ainhoa
authors.initials: A
authors.lastname: Lucía
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy
chemical_list: D000995:Antitubercular Agents; D004337:Drug Carriers